Superiority of Glimepiride Over Sitagliptin in Naive Type 2 Diabetes Patients
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To determine the superiority of glimepiride over sitagliptin in the reduction of HbA1c after
6 months of treatment in patients with monotherapy until the end of the trial.
Secondary Objective:
To evaluate the effect of glimepiride compared to sitagliptin in:
Glucose in fasting conditions; Postprandial glucose; Percentage of patients with HbA1c < 7%
and < 6.5%; Symptomatic Hypoglycemia; Body weight; Percentage of withdrawal and percentage of
patients with rescue therapy; Safety (adverse events and serious adverse events,
hypoglycemia, vital signs and laboratory results).